Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 301–400 of 916
The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma
Hermanns, C., Hampl, V., Hölzer, K., Aigner, A. M., Penkava, J., Frank, N., Martin, D. E., Maier, K., Waldburger, N., Roessler, S. K., et al. (2017) · Oncogene · doi:10.1038/onc.2016.496 · Cited by 46
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 44
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
Rosenbaum, S. R., Tiago, M., Caksa, S., Capparelli, C., Purwin, T. J., Kumar, G., Glasheen, M. Q., Pomante, D., Kotas, D., Chervoneva, I., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110085 · Cited by 49
Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120422 · Cited by 40
“During the emergence of a BRAF inhibitor–resistant cell population (23), an increase in the 130-kDa CSF-1R precursor protein, and the appearance of the higher–molecular weight (165 kDa), mature version of CSF-1R that may be expressed on the cell surface was observed.”
BackgroundCurrent Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang, T., Eldabaje, R., & Yang, L. (2016) · PubMed · Cited by 45
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
Stefan, E., & Bister, K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_4 · Cited by 46
“In contrast, melanoma cells express low basal levels of EGFR, evade this mechanism, and show favorable initial response to BRAFi treatment (Lito et al. 2012; Sun et al. 2014; Holderfield et al. 2014a; Desideri et al. 2015).”
BackgroundEfficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways
Adam, C., Fusi, L., Weiss, N., Goller, S. G., Meder, K., Frings, V. G., Kneitz, H., Goebeler, M., Houben, R., Schrama, D., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.972 · Cited by 40
García‐Hevia, L., Casafont, Í., Oliveira, J. R. P., Terán, N., Fanárraga, M. L., Gallo, J., & Bañobre‐López, M. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.06.009 · Cited by 45
“For instance, Murafenib and Dabrafenib treatments are short-lived and resistance to treatment eventually emerges [44] [–] [46].”
BackgroundVétillard, A., Jonchère, B., Moreau, M., Toutain, B., Henry, C., Fontanel, S., Bernard, A.-C., Campone, M., Guette, C., & Coqueret, O. (2015) · Oncotarget · doi:10.18632/oncotarget.6126 · Cited by 36
“Among several resistance mechanisms, compensatory feedback pathways play an essential role in enabling cell escape in response to targeted therapies [23-27].”
Melanoma brain metastases: Biological basis and novel therapeutic strategies
Phadke, M. A., Özgün, A., Eroglu, Z., & Smalley, K. S. M. (2021) · Experimental Dermatology · doi:10.1111/exd.14286 · Cited by 56
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 41
The MAPK pathway as an apoptosis enhancer in melanoma
Haydn, J. M., Hufnagel, A., Grimm, J., Maurus, K., Schartl, M., & Meierjohann, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2079 · Cited by 45
“Recent studies show that EGFR expression occurs in a significant percentage of BRAF resistant melanomas, and receptor activation, though disadvantageous under normal conditions, becomes beneficial when the MAPK pathway is blocked in BRAFV600E positive melanomas [40].”
BackgroundIdentification and functional analysis of SOX10 phosphorylation sites in melanoma
Cronin, J. C., Loftus, S. K., Baxter, L. L., Swatkoski, S., Guček, M., & Pavan, W. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190834 · Cited by 40
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 43
Phenotype characterization of human melanoma cells resistant to dabrafenib
Cordaro, F. G., De Presbiteris, A. L., Camerlingo, R., Mozzillo, N., Pirozzi, G., Cavalcanti, E., Manca, A., Palmieri, G., Cossu, A., Ciliberto, G., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5963 · Cited by 38
“Since the resistance to B-RAFV600E inhibition in melanoma is reversible and adaptive (15), the resistant cells were characterized, after their expansion, under drug selective pressure.”
BackgroundMethodPeng, S., Long, M., Chen, Q.-S., Yin, Z., Zeng, C., Zhang, W., Wen, Q., Zhang, X., Ke, W., & Wu, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02418-8 · Cited by 43
“Nevertheless, resistance to BRAF and MEK kinase inhibitors is nearly always developed in BRAF (V600E) mutant melanomas [125 – 127].”
Hockings, H., Lakatos, E., Huang, W.-N., Mossner, M., Khan, M. A., Bakali, N., McDermott, J., Smith, K., Baker, A.-M., Graham, T. A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0351 · Cited by 25
“Fitness penalties have been demonstrated in BRAF-resistant melanoma (29) and EGFR-resistant metastatic colorectal cancer (30) but have not been defined during the evolution of resistance to common cytotoxic therapies like platinum chemotherapy.”
Kuperstein, I., Grieco, L., Cohen, D., Thieffry, D., Zinovyev, A. Y., & Barillot, E. (2015) · Mutagenesis · doi:10.1093/mutage/geu078 · Cited by 42
“Although it seems logical to target overexpressed oncogenes in treating cancer patients, experience has shown that the tumour cell often finds compensatory paths and escapes the treatment resulting in tumour resistance and disease relapse (3).”
BackgroundKunz, M., & Hölzel, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9657-1 · Cited by 42
“Together, the impact of MITF-high or MITF-low phenotypes onMAPK resistance emphasizes the importance of phenotypic heterogeneity and phenotype switches as adaptive resistance mechanisms described by several studies [94, 95, 100, 101].”
BackgroundTietze, J. K., Forschner, A., Loquai, C., Mitzel-Rink, H., Zimmer, L., Meiß, F., Rafei-Shamsabadi, D. A., Utikal, J. S., Bergmann, M., Meier, F. E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26149 · Cited by 43
“However, this is reversed when the drug is discontinued [9], which also led to a regression of the resistant cells.”
BackgroundTargeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
Bai, X. L., & Flaherty, K. T. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19394 · Cited by 42
The future of targeted kinase inhibitors in melanoma
Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 39
“In particular, pre-clinical studies have identified autocrine and paracrine activation of EGFR, IGFR, PDGFR-alpha, PDGFR-beta, c-MET, FGFR, and AXL as drivers of targeted therapy resistance (Müller et al., 2014; Nazarian et al., 2010; Patel et al., 2021; Sabbatino et al., 2014; Straussman et al., 2012; Sun et al., 201…”
BackgroundGENOME-WIDE ANALYSIS OF TRIPLE-NEGATIVE PHENOTYPE BREAST TUMORS
Ibragimova, М. K., Tsyganov, M. M., & Litvyakov, N. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.31 · Cited by 37
ACCOMPANYING TRANSCRANIAL MAGNETOTHERAPY IN COMBINATION TREATMENT OF HIGH-GRADE GLIAL BRAIN TUMORS
Popov, I. A., Shikhlyarova, A. I., Frantsiyants, E. M., & Kaplieva, I. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.30 · Cited by 37
Mollaev, M. D., Вихрева, П. Н., Кибардин, А. В., Mayorova, V. E., Kholodenko, R. V., Kulakovskaya, E. A., Pershin, D., Maschan, M. A., & Larin, S. S. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.12 · Cited by 37
STUDY OF BIOLOGICAL ACTIVITY OF DOXORUBICIN CONJUGATE WITH NACETYL-D-GALACTOSAMINE HYDRASONIC LINKER
Pestretsova, A. S., Kozina, D. V., Sokolova, D. V., Pokrovsky, V. S., & Beloglazkina, E. K. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.18 · Cited by 37
INFLUENCE OF HYPOTHYROIDISM ON THE HYPOTHALAMIC-PITUITARYGONADAL AXIS IN RATS WITH GUERIN'S TUMOR
Frantsiyants, E. M., Bandovkina, V. A., Kaplieva, I. V., Surikova, E. I., Neskubina, I. V., Trepitaki, L. K., Shikhlyarova, A. I., Goroshinskaya, I. A., Zhukova, G. V., Nemashkalova, L. A., et al. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.26 · Cited by 37
Androgen receptor is a determinant of melanoma targeted drug resistance
Samarkina, A., Youssef, M. K., Ostano, P., Ghosh, S., Ma, M., Tassone, B., Proust, T., Chiorino, G., Levesque, M. P., Goruppi, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42239-w · Cited by 40
“Conversely, genes of the EGFR and TGF-ß pathways involved in melanoma progression and targeted drug resistance 16,24 were induced by DAB treatment in AR overexpressing cells, to a much greater extent than in control cells (Fig.”
BackgroundStrategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
Obaid, N., Bedard, K., & Huang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030585 · Cited by 39
“Elevations in epidermal growth factor receptor (EGFR) [100], PDGFR [77,101], and IGF1-R [102] have been observed in resistance.”
BackgroundSereti, E., Karagianellou, T., Kotsoni, I., Magouliotis, D. E., Kamposioras, K. V., Ulukaya, E., Sakellaridis, N., Zacharoulis, D., & DIMAS, K. S. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.01.012 · Cited by 41
Melanocyte lineage dynamics in development, growth and disease
Brombin, A., & Patton, E. E. (2024) · Development · doi:10.1242/dev.201266 · Cited by 36
Alberter, B., Klein, C. A., & Polzer, B. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1121099 · Cited by 39
“[2,3]This metastatic progression is driven by pre-existing or de novo acquired mutations mediating therapy resistance in subclones of cancer cells,[4] emphasizing the importance of rapid detection of resistance-mediating mutations.”
BackgroundBRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma
Roux, J., Pagès, C., Malouf, D., Basset‐Séguin, N., Madjlessi, N., Baccard, M., Comte, C., Archimbaud, A., Battistella, M., Viguier, M. A., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000196 · Cited by 36
Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Sahu, A. D., Lee, J. S., Wang, Z., Zhang, G., Iglesias‐Bartolomé, R., Tian, T., Wei, Z., Miao, B., Nair, N. U., Ponomarova, O., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188323 · Cited by 42
“…whose over-expression rescues cancer cells, using a set of genes that were previously shown to mediate cancer drug resistance (Mills et al , 2013; Sun et al , 2014; Fong et al , 2015; Lin et al , 2015; Rathert et al , 2015; Stuhlmiller et al , 2015; Falkenberg et al , 2016; Yamaguchi et al ,…”
BackgroundBruneel, K., Verstappe, J., Vandamme, N., & Berx, G. (2020) · Cancers · doi:10.3390/cancers12082248 · Cited by 37
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 52
Diazzi, S., Baeri, A., Fassy, J., Lecacheur, M., Marín-Béjar, O., Girard, C. A. J., Lefevre, L., Lacoux, C., Irondelle, M., Mounier, C. M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115295 · Cited by 40
Lucarini, V., Melaiu, O., D’Amico, S., Pastorino, F., Tempora, P., Scarsella, M., Pezzullo, M., Ninno, A. D., Doria, V., Cilli, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02525-9 · Cited by 38
“Consistently, recent use of TGFβblocking antibodies has been shown to overcome resistance to anti-PD-1 therapy by reactivating the antitumor immune response in colorectal cancer and melanomas [12, 14].”
BackgroundNon-small-cell lung cancer: how to manage BRAF-mutated disease
Guaitoli, G., Zullo, L., Tiseo, M., Dankner, M., Rose, A. A. N., & Facchinetti, F. (2023) · Drugs in Context · doi:10.7573/dic.2022-11-3 · Cited by 37
Biofabrication and Monitoring of a 3D Printed Skin Model for Melanoma
Vázquez‐Aristizabal, P., Henriksen‐Lacey, M., García‐Astrain, C., de Aberasturi, D. J., Langer, J., Epelde, C., Litti, L., Liz‐Marzán, L. M., & Izeta, A. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401136 · Cited by 38
Loss‐of‐function screens of druggable targetome against cancer stem‐like cells
Song, M., Lee, H., Nam, M., Jeong, E., Kim, S., Hong, Y., Kim, N., Yim, H. Y., Yoo, Y., Kim, J. S., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600953 · Cited by 36
Hegedüs, L., Garay, T., Molnár, E., Varga, K., Bilecz, Á., Török, S., Padányi, R., Pászty, K., Wolf, M., Grusch, M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30503 · Cited by 39
“Nevertheless, a number of BRAF mutant melanomas show limited response due to intrinsic resistance and initially responding patients often relapse due to acquired resistance.(5,6) Recent advances in immunotherapy have led to important improvements in clinical outcome.”
BackgroundWelinder, C., Pawłowski, K., Szász, A. M., Yakovleva, M., Sugihara, Y., Malm, J., Jönsson, G. B., Ingvar, C., Lundgren, L., Baldetorp, B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176167 · Cited by 39
LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells
Han, S., Yan, Y., Ren, Y., Hu, Y., Wang, Y., Chen, L., Zhi, Z., Zheng, Y., Shao, Y., & Liu, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3145 · Cited by 36
“S8) as well as in RAFi-treated patient samples (29).”
BackgroundPriantti, J. N., Vilbert, M., Madeira, T., de Moraes, F. C. A., Hein, E. C. K., Saeed, A., & Cavalcante, L. L. (2023) · Cancers · doi:10.3390/cancers15153754 · Cited by 38
New role of ID3 in melanoma adaptive drug-resistance
Sachindra, Larribère, L., Novak, D., Wu, H., Hüser, L., Granados, K., Orouji, E., & Utikal, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.22698 · Cited by 37
“Although the mechanisms by which vemurafenib regulates ID3 are not yet known, suppression of SOX10 was described to activate the TGFβ-EGFR-PDGFRB signaling and to lead to BRAF inhibitor resistance [27].”
BackgroundAnti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma
Ercolano, G., Cicco, P. D., Frecentese, F., Saccone, I., Corvino, A., Giordano, F., Magli, E., Fiorino, F., Severino, B. U., Calderone, V., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00066 · Cited by 36
“Actually, the most clinically used small molecule targeted drugs are the specific BRAF, MEK, or c-KIT inhibitors but, unfortunately, resistance develops invariably (Sun et al., 2014).”
BackgroundMetabolic rewiring in melanoma drug-resistant cells
Bristot, I. J., Dias, C. K., Chapola, H., Parsons, R. B., & Klamt, F. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102995 · Cited by 35
NRF2 Enables EGFR Signaling in Melanoma Cells
Kreß, J. K. C., Jessen, C., Marquardt, A., Hufnagel, A., & Meierjohann, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083803 · Cited by 34
“Here, suppression of SOX10 leads to the elevation of transforming growth factor β (TGFβ), which causes a profound upregulation of EGFR.”
BackgroundInfluentialTowards integrative systems pharmacology models in oncology drug development
van Hasselt, J. G. C., & van der Graaf, P. H. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.06.004 · Cited by 37
Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway
Sun, J., Zhao, H., Shen, C., Li, S., Zhang, W., Ma, J., Li, Z., Zhang, M., & Yang, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02949-2 · Cited by 37
“The expression of EGFR is modulated by various factors, such as ligand-induced endocytosis, phosphorylation, and ubiquitination, and the balance of positive and negative feedback maintains the normal expression level of EGFR [40, 41].”
BackgroundBioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers
Sanati, M., Figueroa‐Espada, C. G., Han, E. L., Mitchell, M. J., & Yavari, S. A. (2024) · ACS Nano · doi:10.1021/acsnano.4c11259 · Cited by 33
Link, W. (2019) · Springer eBooks · doi:10.1007/978-3-030-18722-4_3 · Cited by 33
Lee, B., Sahoo, A., Sawada, J., Marchica, J., Sahoo, S., Layng, F. I., Finlay, D., Mazar, J., Joshi, P. K., Komatsu, M., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.038 · Cited by 37
“Since the majority of patients treated with MAPK inhibitors develop resistance and relapse (Sun et al., 2014), there is a need to identify molecular mechanisms of drug resistance and to develop novel drug targets,”
BackgroundAutophagy Inhibition in BRAF-Driven Cancers
Foth, M., & McMahon, M. (2021) · Cancers · doi:10.3390/cancers13143498 · Cited by 34
“Moreover, point mutations in RAS or MEK1 [34,39–43], as well as upregulation of EGFR, PDGFR, or FGFR3 [44,45], or persistent formation of the eIF4F translation initiation complex [46], have been described to result in re-activation of the MAPK pathway and therapy resistance.”
BackgroundPillai, M., & Jolly, M. K. (2021) · iScience · doi:10.1016/j.isci.2021.103111 · Cited by 37
Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
Parker, R. S., Vella, L. J., Xavier, D., Amirkhani, A., Parker, J., Cebon, J. S., & Molloy, M. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00095 · Cited by 34
Sarrabayrouse, G., Pich-Bavastro, C., Teiti, I., & Tilkin‐Mariame, A. F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30422 · Cited by 37
Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
Saei, A., & Eichhorn, P. J. A. (2019) · Cancers · doi:10.3390/cancers11081176 · Cited by 35
“SOX10-mediated FOXD3 upregulation occurs rapidly following BRAF inhibition; however, SOX10-mediated repression of TGFβ/EGFR/PDGFRβ occurs following the prolonged treatment with BRAF inhibitors, suggesting that differential drug-induced transcriptional states may switch SOX10 from an oncogene to a tumour repressor [66].”
BackgroundInfluentialEfficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy
Wang, S. J., Li, R., Ng, T. S. C., Luthria, G., Oudin, M. J., Prytyskach, M., Köhler, R. H., Weissleder, R., Lauffenburger, D. A., & Miller, M. A. (2020) · Science Advances · doi:10.1126/sciadv.aaz8521 · Cited by 36
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 37
“The best hit was the Epidermal growth factor receptor gene (EGFR), a wellknown BRAFi-resistance gene (Sun et al, 2014; Shaffer et al, 2017).”
BackgroundResultInfluentialMechanisms of Functional Pleiotropy of p73 in Cancer and Beyond
Logotheti, S., Richter, C., Murr, N., Spitschak, A., Marquardt, S., & Pützer, B. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.737735 · Cited by 35
Ahuja, S., & Zaheer, S. (2023) · Cell Biology International · doi:10.1002/cbin.12097 · Cited by 37
“In the recent past, scientists have tried to discover potent TGF ‐ β signaling inhibitors, which can act as a means to suppress cancer treatment resistance (Jenkins et al., 2015; Li, Song, et al., 2019; Sun et al., 2014; Wang et al., 2019).”
BackgroundBOK displays cell death‐independent tumor suppressor activity in non‐small‐cell lung carcinoma
Moravčíková, E., Krepela, E., Donnenberg, V. S., Donnenberg, A. D., Benková, K., Rabachini, T., Fernández‐Marrero, Y., Bachmann, D., & Kaufmann, T. (2017) · International Journal of Cancer · doi:10.1002/ijc.30906 · Cited by 35
“Furthermore, the quantitative surface proteomics profiling showed upregulation of EGFR by TGFβ (Figure 6) suggesting the involvement of JUN N-terminal kinases pathway leading to JUN transcription factor activation (40) that binds to EGFR responsive element.”
BackgroundYu, M., Gu, Q., & Xu, J. (2018) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-017-0092-8 · Cited by 36
Schmid, S., Siano, M., Joerger, M., Rodriguez, R., Müller, J., & Früh, M. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.008 · Cited by 31
Landsberg, J., Tüting, T., Barnhill, R. L., & Lugassy, C. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.11.013 · Cited by 31
Sammons, S. L., Brady, D. C., Vahdat, L. T., & Salama, A. K. S. (2016) · Melanoma Management · doi:10.2217/mmt-2015-0005 · Cited by 33
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells
Hartman, M. L., Różański, M., Osrodek, M., Zaleśna, I., & Czyż, M. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.140 · Cited by 31
Kavran, A. J., Stuart, S. A., Hayashi, K. R., Basken, J., Brandhuber, B. J., & Ahn, N. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113535119 · Cited by 36
“For example, growth factor receptors and ligands, EMT-like and neural crest markers known to promote resistance (e.g., PDGFRB, EGFR, AXL, NGFR, and WNT5A) (12, 21, 42, 48, 49) increased with continuous drug treatment, while genes associated with differentiation to the melanocyte lineage (e.g., MITF, TYR, MLANA, and SO…”
BackgroundInfluentialEarly Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 34
Li, Z., Jiang, Y., Liu, J., Fu, H., Yang, Q., Song, W., & Li, Y. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5532 · Cited by 33
Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia
Sarvaria, A., Topp, Z. Z., & Saven, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4134 · Cited by 31
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma
Boregowda, R. K., Medina, D. J., Markert, E. K., Bryan, M. A., Chen, W., Chen, S., Rabkin, A., Vido, M. J., Gunderson, S., Chekmareva, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8822 · Cited by 32
“Up-regulation of the expression of EGF-R, PDGFRβ, AXL and IGF-1R in melanoma cells that have developed resistance to BRAF V600E targeted therapy [19–25] results in reactivation of the MAPK and the PI3K/AKT pathways.”
BackgroundTolk, H., Satzger, I., Mohr, P., Zimmer, L., Weide, B., Schäd, S. G., & Gutzmer, R. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000169 · Cited by 34
A Nonquiescent “Idling” Population State in Drug-Treated, BRAF-Mutated Melanoma
Paudel, B. B., Harris, L. A., Hardeman, K. N., Abugable, A. A., Hayford, C. E., Tyson, D. R., & Quaranta, V. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.01.016 · Cited by 33
BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1
Grimm, J., Hufnagel, A., Wobser, M., Borst, A., Haferkamp, S., Houben, R., & Meierjohann, S. (2018) · Oncogenesis · doi:10.1038/s41389-018-0082-2 · Cited by 34
T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma
Barceló, C., Sisó, P., Maiques, Ó., García‐Mulero, S., Pamplona, R. S., Navaridas, R., Megino‐Luque, C., Felip, I., Urdanibia, I., Eritja, N., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.11.014 · Cited by 32
Hoang, V. T., Nyswaner, K. M., Torres‐Ayuso, P., & Brognard, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012365 · Cited by 31
Plasticity and Functional Heterogeneity of Cancer-Associated Fibroblasts
Flynn, J. M., Thadani, N., Gallagher, E. E., Azzaro, I., Bodnar, C. M., McCarty, C. P., Romano, G., Webster, M. R., & Capparelli, C. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3037 · Cited by 39
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
“Acquired EGFR and platelet-derived growth factor receptor B (PDGFRB) expression has been found after resistance to BRAF and MEK inhibitors as a result of an adaptive response of the cancer cell population during drug selection (96).”
BackgroundCohen-Solal, K., Kaufman, H. L., & Lasfar, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12666 · Cited by 30
“Consistent with this hypothesis, the expression of SOX10 in LOXIMVI melanoma cells (lacking SOX10 and expressing high EGFR levels) increased their sensitivity to vemurafenib (Sun et al., 2014).”
BackgroundResultThe lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
Sanlorenzo, M., Vujic, I., Esteve‐Puig, R., Lai, K., Vujic, M., Lin, K. C., Posch, C., Dimon, M. T., Moy, A., Zekhtser, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27643-3 · Cited by 31
Kreuzaler, P. A., Clarke, M. A., Brown, E., Wilson, C. H., Kortlever, R. M., Piterman, N., Littlewood, T. D., Evan, G. I., & Fisher, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903485116 · Cited by 32
“Such heterogeneity fuels tumor evolution and contributes to the failure of durable therapeutic responses and to subsequent relapse (4, 5).”
BackgroundManagement of V600E and V600K BRAF-Mutant Melanoma
Haugh, A. M., & Johnson, D. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0680-z · Cited by 33
The histone demethylase PHF8 regulates TGFβ signaling and promotes melanoma metastasis
Moubarak, R. S., de Pablos-Aragoneses, A., Ortiz-Barahona, V., Gong, Y., Gowen, M. F., Dolgalev, I., Shadaloey, S. A. A., Argibay, D., Karz, A., Itter, R. V., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi7127 · Cited by 30
“TGF signaling can cross-talk with the mitogen-activated protein kinase (MAPK) pathway and contribute to resistance to B-Raf proto-oncogene (BRAF) and MAPK kinase (MEK) inhibitors (51).”
BackgroundIndini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 33
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
Yao, T.-W., Zhang, J., Prados, M., Weiss, W. A., James, C. D., & Nicolaides, T. P. (2016) · Oncotarget · doi:10.18632/oncotarget.11882 · Cited by 30
“Interestingly, BRAF inhibitor insensitive melanoma regains its sensitivity after a temporary withdrawal of drug [12, 20].”
BackgroundNeuropilin: Handyman and Power Broker in the Tumor Microenvironment
Niland, S., & Eble, J. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35582-1_3 · Cited by 33
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29
“Upregulation of EGFR and plateletderived growth factor receptor (PDGFRb) by TGF-b signaling leads to resistance to BRAF and MEK inhibitors (36), and upregulation of PDGFRa by the Sonic Hedgehog Homolog (Shh) pathway confers resistance to BRAF inhibition in metastatic BRAF(V600E) melanoma (37).”
BackgroundCholangiocarcinoma Targeted Therapies
Ellis, H., Braconi, C., Valle, J. W., & Bardeesy, N. M. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.11.005 · Cited by 31
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Yakubov, R., Kaloti, R., Persaud, P., McCracken, A., Zadeh, G. M., & Bunda, S. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04930-w · Cited by 34
“Moreover, HIF-1α interacts with the RTK pathway, with ERK amplifying its effects by upregulating hypoxia-responsive genes that sustain GSCs, drive EMT-like traits, and exacerbate intratumoral heterogeneity, promoting tumor plasticity, aggressiveness, and therapy resistance [16, 123, 196].”
Kenessey, I., Kramer, Z., István, L., Cserepes, M., Garay, T., Hegedűs, B., Dobos, J., Tímár, J., & Tóvári, J. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000488 · Cited by 33
Larribère, L., & Utikal, J. S. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00111 · Cited by 31
“In addition, the authors observed a reversibility of this resistant state when taking the cells off the drug, a characteristic which could offer an alternative to a subpopulation of BRAFmutated patients who has stopped its treatment (Sun et al., 2014).”
BackgroundWei, W., Geer, M. J., Guo, X., Dolgalev, I., Sanjana, N. E., & Neel, B. G. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221563 · Cited by 31
“…strategy for malignancies driven by RTKs or TK fusions, “ cycling ” KRAS mutants, or, in combination with other pathway inhibitors for combating adaptive resistance (Fedele et al., 2021; Fedele et al., 2018; Lou et al., 2019; Mainardi et al., 2018; Ryan and Corcoran, 2018; Sun et al., 2014).”
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation
Erdem‐Eraslan, L., Gao, Y., Kloosterhof, N. K., Atlasi, Y., Demmers, J., Sacchetti, A., Kros, J. M., Smitt, P. A. E. S., Aerts, J. G. J. V., & French, P. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.006 · Cited by 31
“Finally, we demonstrate using stably expressing cell lines that EGFRvIII and EGFL858R display reduced growth and migration compared to EGFR wildtype expressing cells.”
BackgroundInfluentialThe Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma
Zhan, Y., Dahabieh, M. S., Rajakumar, A., Dobocan, M. C., M’Boutchou, M.-N., Gonçalves, C., Lucy, S. L., Pettersson, F., Topisirović, I., van Kempen, L. C. L. T., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.11 · Cited by 29
Nagasawa, I., Kunimasa, K., Tsukahara, S., & Tomida, A. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.062 · Cited by 33
Tokuda, E. Y., Jones, C. E., & Anseth, K. S. (2017) · Integrative Biology · doi:10.1039/c6ib00229c · Cited by 29
Molnár, E., Garay, T., Donia, M., Baranyi, M., Rittler, D., Berger, W., Tímár, J., Grusch, M., & Hegedűs, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184484 · Cited by 30
“Activation of the EGFR pathway was also identified in BRAF-inhibitor-resistant melanoma [7,8,36].”
Background
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.